Virax Biolabs Group Ltd (VRAX) — Titan Protect Analysis

VRAX

Virax Biolabs Group Ltd

Healthcare · ·

$0.21

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.78

Based on estimated future earnings — lower means cheaper

Rev Growth

-67.5%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-83.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$1.00

+369% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Virax Biolabs Group Ltd

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary

https://viraxbiolabs.com

Country: United Kingdom Employees: 19 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.319

Positive but modest risk-adjusted returns

Kelly Fraction

0.0038

Marginal edge — very small allocation suggested

Calmar Ratio

-0.581

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-57.2%

Historical annualised return based on price data

Max Drawdown

-98.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.05

Moves slightly more than the broader market

52W High

$1.14

81% below the year high

52W Low

$0.10

113% above the year low

Avg Volume

29,959,511

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.22

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

10.60

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-160,788.3%

Profit from core operations before interest and tax

Free Cash Flow

$-3,539,977

Negative — the business is spending more than it generates

Revenue (TTM)

$2,986

Total revenue over the last 12 months

Net Income

$-5,643,591

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$1.00

Target Median

$1.00

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go